Please use this identifier to cite or link to this item: https://scidar.kg.ac.rs/handle/123456789/11366
Title: Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives
Authors: Lazarević B.
Rilak, Ana
Bugarčić Z.
Journal: European Journal of Medicinal Chemistry
Issue Date: 15-Dec-2017
Abstract: © 2017 Elsevier Masson SAS Metallodrugs offer potential for unique mechanism of drug action based on the choice of the metal, its oxidation state, the types and number of coordinated ligands and the coordination geometry. This review illustrates notable recent progress in the field of medicinal bioinorganic chemistry as many new approaches to the design of innovative metal-based anticancer drugs are emerging. Current research addressing the problems associated with platinum drugs has focused on other metal-based therapeutics that have different modes of action and on prodrug and targeting strategies in an effort to diminish the side-effects of cisplatin chemotherapy. Examples of metal compounds and chelating agents currently in clinical use, clinical trials or preclinical development are highlighted.
URI: https://scidar.kg.ac.rs/handle/123456789/11366
Type: Review
DOI: 10.1016/j.ejmech.2017.04.007
ISSN: 02235234
SCOPUS: 85018782494
Appears in Collections:Institute for Information Technologies, Kragujevac
[ Google Scholar ]

Page views(s)

41

Files in This Item:
File Description SizeFormat 
PaperMissing.pdf
  Restricted Access
29.86 kBAdobe PDFThumbnail
View/Open


Items in SCIDAR are protected by copyright, with all rights reserved, unless otherwise indicated.